CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
CervoMed Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.31+0.07 (+3.12%)
Close on Oct 19, 2026
- Market cap
- $23.66M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.77 (−67.37%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CervoMed Inc. saw revenue fall 95.7% to $331.30K over the twelve months to Jun 30, 2026.
Revenue
$331.30K
-95.7% vs. a year earlier
Operating income
-$31.16M
TTM Q2 2026
EPS, diluted
-$3.21
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $23.66M
- P/E ratio
- –
- Price to sales
- 71.43
- Price to book
- 1.03
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $331.30K
- Net income
- -$30.35M
- EPS, diluted
- -$3.21
- Book value per share
- $2.24
- Diluted shares
- 10M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$331.30K-95.7% YoY
Gross profit
–
Operating income
-$31.16M
Net income
-$30.35M
EPS, diluted
-$3.21
Free cash flow
–
Reported periodTrailing twelve months